Fundraising Fox
/Companies
Sign in

Envisia Therapeutics

Morrisville, US · Founded 2013 · Delaware corporation · 7 known investors

Find your way into Envisia Therapeutics

328 people in our graph share verified history with the Envisia Therapeutics team — schools, employers, funds. One of them is your warm intro.

Ed Fieldunlockedknows Eric Linsley · together at BioLabs North Carolina (overlapped)
knows the team · via Inspire Pharmaceuticals
knows the team · via Opus Genetics
×3knows the team · via Trefoil Therapeutics
×2knows the team · via UC Irvine
×2knows the team · via Clearside Biomedical
Biotech

Founders & leadership

BYBen Yerxa
Ben YerxaPresident2015–2017Dr. Yerxa brings over 30 years of pharmaceutical and biotechnology leadership experience across ophthalmology, rare disease, and other therapeutic areas, including roles as a corporate officer at Inspire Pharmaceuticals and CEO of Foundation Fighting Blindness, where he oversaw drug discovery through commercialization, regulatory submissions, and technology licensing. He holds more than 50 U.S. patents and has contributed to the development of multiple drug candidates and approved therapeutics.
ELEric Linsley
Eric LinsleyChief Financial Officer2015–2017Eric Linsley is Managing General Partner of BioInnovation Capital, overseeing the firm's North Carolina lab and life sciences investments. He previously served as Chief Financial Officer of TriPath Imaging, a medical device company acquired by Becton Dickinson in 2006, and before that at AutoCyte, which completed an IPO in 1997; he also spent over a decade at Pappas Ventures investing in therapeutics, diagnostics, and medical devices.

Board

EMEd Mathers
Ed MathersBoard directorPartner at New Enterprise Associates (NEA)
SBStephen Bloch
Stephen BlochBoard directorGeneral Partner at Canaan Partners
SR
Seth RudnickBoard directorInvestor at Canaan Partners
NF
Neal FowlerBoard director
AG
Adrienne GravesBoard director
GP
Gary PhillipsBoard director

Investors · 7

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ed Mathers · board

How we know: board seat on SEC Form D · Not right? Tell us

Pappas Capitallisted by Pappas CapitalDurham

How we know: Pappas Capital's portfolio page · Not right? Tell us

+ND CapitalreportedWoodside · $540K – $5.4M

How we know: funding news · Not right? Tell us

ARCH Venture PartnersreportedChicago · $50K – $250M

How we know: funding news · Not right? Tell us

Illumina VenturesreportedFoster City

How we know: funding news · Not right? Tell us

OMX VenturesreportedLincolnshire

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$14.7M disclosed across 2 rounds · 2015–2016

▶$10.1MraisedMar 2016 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William YelleDirector
  • Gary PhillipsDirector
  • Ed MathersDirector
  • Adrienne GravesDirector
  • Neal FowlerDirector
  • Eric LinsleyExecutive Officer
  • Ben YerxaExecutive Officer
  • Stephen BlochDirector
Offering amount
$16.5M
Amount sold
$10.1M
Proceeds to insiders
$500K
First sale
Mar 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedOct 2015 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ed MathersDirector
  • Adrienne GravesDirector
  • Stephen BlochDirector
  • Ben YerxaExecutive Officer
  • Gary PhillipsDirector
  • Seth RudnickDirector
  • Neal FowlerDirector
  • Eric LinsleyExecutive Officer
Offering amount
$5.1M
Amount sold
$4.6M
Proceeds to insiders
$500K
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Envisia Therapeutics went on to found or lead other companies.

Stephen BlochDirectorFounded Allyx Therapeutics, Inc.Christy ShafferExecutive OfficerFounded Opus Genetics

Frequently asked questions

Who are Envisia Therapeutics's investors?
Envisia Therapeutics's investors include Canaan Partners, New Enterprise Associates (NEA), Pappas Capital, +ND Capital, ARCH Venture Partners, Illumina Ventures, OMX Ventures.
How much funding has Envisia Therapeutics raised?
Envisia Therapeutics has disclosed $14.7M raised across 2 rounds.
Where is Envisia Therapeutics headquartered?
Envisia Therapeutics is headquartered in Morrisville, US.